Expert Review of Vaccines最新文献

Evaluation of varicella outbreak control following implementation of a two-dose free vaccination policy in Wuxi, China (2014-2024). 中国无锡市实施两剂免费疫苗接种政策后水痘疫情控制评估（2014-2024年）

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-31 Epub Date: 2026-04-07 DOI: 10.1080/14760584.2026.2653758

Min Yang, Lingling Wang, Xuwen Wang, Lu Zhou, Xu Yang, Jingfeng Jiang, Kun Yang, Qiujin Chen, Shixin Xiu, Yihan Lu

{"title":"Evaluation of varicella outbreak control following implementation of a two-dose free vaccination policy in Wuxi, China (2014-2024).","authors":"Min Yang, Lingling Wang, Xuwen Wang, Lu Zhou, Xu Yang, Jingfeng Jiang, Kun Yang, Qiujin Chen, Shixin Xiu, Yihan Lu","doi":"10.1080/14760584.2026.2653758","DOIUrl":"10.1080/14760584.2026.2653758","url":null,"abstract":"Background: Varicella is a common vaccine-preventable disease in China, with frequent outbreaks in schools and communities. In late 2018, Wuxi implemented a free two-dose varicella vaccination policy. This study evaluated its epidemiological impact.Research design and methods: We analyzed outbreak data from Wuxi during 2014-2024. Main outcomes included outbreaks, cases, and outbreak duration. Interrupted time series and ARIMA models were used to evaluate temporal trends. Fixed-effects regression examined the association between vaccination coverage and outbreak indicators. Spatial analysis identified clustering patterns before and after policy.Results: After policy implementation (2019-2024), outbreaks decreased by about 56% and cases decreased by about 60%. Annual percent change shifted from strongly positive before the policy (APC > 140%, p < 0.05) to negative after the policy (APC < -30%, p < 0.05). Each 1% increase in two-dose coverage was associated with reductions of 0.82 outbreaks (p < 0.001), 21.67 cases (p < 0.001), and 2.55 days in duration (p < 0.05). Spatial clustering weakened over time.Conclusion: The free two-dose vaccination policy was associated with substantial reductions in varicella outbreaks in Wuxi. Sustaining high two-dose coverage remains important. Interpretation should consider the ecological design, lack of individual-level vaccination data, and potential COVID-19-related confounding.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2653758"},"PeriodicalIF":4.8,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147573055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccine hesitancy among 0-6-year-olds' guardians in Chongqing: a cross-sectional survey revealing how immunization program managers' robust comprehensive capacity for adverse events following immunization (AEFI) management mitigates hesitancy. 重庆市0-6岁儿童监护人的疫苗犹豫：一项横断面调查揭示了免疫规划管理者对免疫不良事件管理的强大综合能力如何减轻犹豫。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-03-06 DOI: 10.1080/14760584.2026.2640140

Binyue Xu, Qing Wang, Jiawei Xu, Jianqiao Li, Ningpei Bai, Chunbei Zhou

{"title":"Vaccine hesitancy among 0-6-year-olds' guardians in Chongqing: a cross-sectional survey revealing how immunization program managers' robust comprehensive capacity for adverse events following immunization (AEFI) management mitigates hesitancy.","authors":"Binyue Xu, Qing Wang, Jiawei Xu, Jianqiao Li, Ningpei Bai, Chunbei Zhou","doi":"10.1080/14760584.2026.2640140","DOIUrl":"10.1080/14760584.2026.2640140","url":null,"abstract":"Background: Vaccine hesitancy hinders optimal immunization coverage with fear of adverse events following immunization (AEFI) as a key driver. This study examines how robust district-level AEFI management capacity alleviates vaccine hesitancy among guardians of 0-6-year-olds in Chongqing, China.Research design and methods: A cross-sectional survey was conducted from January to March 2023. Guardians were recruited via multistage stratified sampling. Two-level multivariate modeling and structural equation modeling (SEM) were employed to explore direct and indirect effects of AEFI management capacity on hesitancy.Results: Among 2664 valid samples, the mean hesitancy score was 21.9 ± 4.5, with 19.5% self-reporting hesitancy. AEFI incident response capability (β = -1.087, 95% CI: -2.053~-0.121), approval of district AEFI committees (β = -1.202, 95% CI: -1.839~-0.565) and higher vaccination knowledge (β = -0.377, 95% CI: -0.571~-0.183) were negatively correlated with hesitancy. SEM further demonstrated that district-level AEFI management capacity indirectly decreases the guardians' hesitancy by improving their approval of AEFI committees (β = 0.183, 95% CI: 0.093 ~ 0.284).Conclusions: Robust district AEFI management and higher vaccination knowledge alleviate guardians' hesitancy. Targeted interventions can boost trust and coverage. These findings provide actionable insights for refining immunization policies and practice in China and other countries facing similar challenges.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2640140"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147325173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A human Lyme disease vaccine: two steps forward on the path to prevention. 人类莱姆病疫苗：在预防道路上前进了两步。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2025-12-25 DOI: 10.1080/14760584.2025.2607482

Raphael Simon, Erik Lamberth, James H Stark, Julie M Skinner

{"title":"A human Lyme disease vaccine: two steps forward on the path to prevention.","authors":"Raphael Simon, Erik Lamberth, James H Stark, Julie M Skinner","doi":"10.1080/14760584.2025.2607482","DOIUrl":"10.1080/14760584.2025.2607482","url":null,"abstract":"Introduction: Lyme disease is caused by the tick-borne spirochete pathogen Borrelia burgdorferi sensu lato (s.l.). Outer surface protein A (OspA) is expressed by B. burgdorferi s.l. while in the tick and antibodies against OspA introduced into the tick with the bloodmeal can prevent transmission. OspA-based vaccines have been validated in people, however, there are currently no available human Lyme disease vaccines. Hexavalent OspA vaccine VLA15 is designed to cover the dominant B. burgdorferi s.l. genospecies causing disease in North America and Europe and is currently the most advanced candidate human Lyme disease vaccine in clinical development.Areas covered: A historical retrospective of the discovery and evolving burden of Lyme disease is covered, as well as relevant aspects of the vector biology, preclinical research underpinning development of VLA15, and its clinical development to date.Expert opinion: Lyme disease has expanded over the past two decades in both incidence and geographic footprint and is anticipated to continue to increase in the future due to changing climate and human encroachment into wildlife areas. VLA15 is currently in the last stage of clinical development, and if found to be safe and efficacious, may offer an important prophylactic modality for prevention of Lyme disease.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2607482"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suboptimal vaccine uptake and vaccine hesitancy in the United States: current challenges and future directions. 美国的次优疫苗摄取和疫苗犹豫：当前挑战和未来方向。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-04-01 DOI: 10.1080/14760584.2026.2653756

Robert A Bednarczyk

{"title":"Suboptimal vaccine uptake and vaccine hesitancy in the United States: current challenges and future directions.","authors":"Robert A Bednarczyk","doi":"10.1080/14760584.2026.2653756","DOIUrl":"10.1080/14760584.2026.2653756","url":null,"abstract":"Introduction: Vaccination is an important tool to prevent infectious disease morbidity and mortality. Increased vaccine hesitancy and declining vaccination are contributing to larger infectious disease outbreaks. This review presents the current state of research and knowledge on vaccine hesitancy, focused on the United States (US).Areas covered: This review covers the history of vaccination and vaccine hesitancy, recent and ongoing outbreaks, and updates in understanding of vaccine hesitancy and use of new psychology-based tools to address it. Articles for inclusion were sourced from extant understanding of the vaccine hesitancy literature as well as PubMed searches to ensure appropriate context.Expert opinion: Population-level outreach and effective communication about vaccines is a central component to addressing vaccine hesitancy and restoring and maintaining trust in the vaccination system. With new ways of understanding vaccine hesitancy rooted in the psychology of decision-making, there is a need for research into outreach, message development, and implementation, within the information and social media environment that allows even faster dissemination of mis- and dis-information. Balancing the rigor of communications and implementation research with the need for timely communications is a pressing challenge to be faced by public health and medical professionals when addressing vaccine hesitancy.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2653756"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond aggregate estimates: stratified self-controlled case series analyses and insights into COVID-19 vaccine safety. 超越总体估计：分层自我控制病例系列分析和对COVID-19疫苗安全性的见解。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-04-01 DOI: 10.1080/14760584.2026.2653749

Laith J Abu-Raddad, Hiam Chemaitelly

引用次数: 0

Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study. 佐剂rsvpref3疫苗在COPD患者中的吸收和有效性：一项丹麦全国队列研究

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-03-10 DOI: 10.1080/14760584.2026.2641671

Maria João Fonseca, Stanislava Bratković, Yunus Çolak, Marie Helleberg, Jørgen Vestbo, Sara Burns, Maria Spanggaard, Kasper Løwe Lundgren, Foteini Gkalapi, Katherine Theiss-Nyland

{"title":"Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study.","authors":"Maria João Fonseca, Stanislava Bratković, Yunus Çolak, Marie Helleberg, Jørgen Vestbo, Sara Burns, Maria Spanggaard, Kasper Løwe Lundgren, Foteini Gkalapi, Katherine Theiss-Nyland","doi":"10.1080/14760584.2026.2641671","DOIUrl":"10.1080/14760584.2026.2641671","url":null,"abstract":"Background: Individuals with chronic obstructive pulmonary disease (COPD) face increased risk of severe respiratory syncytial virus (RSV)-related outcomes. We assessed the uptake of adjuvanted-RSVPreF3 and its effectiveness against RSV hospitalization in such individuals.Research design and methods: We assembled a Danish nationwide cohort of individuals aged ≥ 60 years with COPD during the 2024/25 RSV season. Vaccinated and unvaccinated individuals were matched using exact and propensity score matching resulting in balanced groups. Individuals were followed from 21 days post-vaccination until the earliest of event, end of data availability, migration, RSV vaccination, or death. Vaccine effectiveness was estimated as (1 - incidence rate ratio [IRR]) x 100, where IRRs were calculated using observed event counts and accumulated person-time. Confidence intervals (CIs) were based on Poisson distributions.Results: Among 126,249 eligible individuals, 7,448 (5.9%) received adjuvanted-RSVPreF3. RSV hospitalization rates per 100,000 person-years were 0.0 (95% CI: 0.0-58.0) for vaccinated individuals and 200.6 (165.6 - 240.8) for unvaccinated individuals, yielding an effectiveness of 100.0% (71.1-100.0). Incidences of other RSV-related outcomes were lower among vaccinated individuals.Conclusions: Adjuvanted-RSVPreF3 is highly effective in preventing RSV hospitalization in individuals aged ≥60 years with COPD. Disease outcomes could be improved by incorporating RSV vaccination into routine COPD management.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2641671"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-11 DOI: 10.1080/14760584.2026.2629653

引用次数: 0

Preventing COVID-19 in at-risk populations: moving toward next-generation mRNA-1283 COVID-19 vaccine to address current challenges. 在高危人群中预防COVID-19：开发下一代mRNA-1283 COVID-19疫苗以应对当前挑战

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-03-03 DOI: 10.1080/14760584.2026.2632657

Joseph B Domachowske, Gregory D Zimet, William Hanage, Ekkehard Beck, Preeti Sule, Rahnuma Wahid, Nevena Vicic

{"title":"Preventing COVID-19 in at-risk populations: moving toward next-generation mRNA-1283 COVID-19 vaccine to address current challenges.","authors":"Joseph B Domachowske, Gregory D Zimet, William Hanage, Ekkehard Beck, Preeti Sule, Rahnuma Wahid, Nevena Vicic","doi":"10.1080/14760584.2026.2632657","DOIUrl":"10.1080/14760584.2026.2632657","url":null,"abstract":"Introduction: Next-generation COVID-19 vaccines hold promise to reduce severe outcomes in populations most at risk. While the original mRNA COVID-19 vaccine, mRNA-1273, targets the full-length SARS-CoV-2 spike protein, mRNA-1283 is a novel next-generation mRNA COVID-19 vaccine that specifically targets immunodominant domains within the spike protein.Areas covered: This review summarizes literature on the development of mRNA-1283, from its design and preclinical evaluation to phase 1-3 clinical trial findings, with a particular focus on immunogenicity and efficacy in at-risk populations, specifically older adults and adults with comorbidities. The potential public health impact of this next-generation vaccine is explored, along with ongoing challenges facing COVID-19 vaccination.Expert opinion: Phase 1-3 clinical trials demonstrated that mRNA-1283 was well-tolerated and no safety concerns were identified. Furthermore, mRNA-1283 demonstrated higher point estimates of immunogenicity and relative vaccine efficacy than mRNA-1273, including among older adults and individuals with underlying conditions who are most susceptible to severe COVID-19. Initial modeling studies indicate that mRNA-1283 could prevent more hospitalizations than current COVID-19 vaccines. Evidence to date suggests that the novel next-generation mRNA-1283 vaccine holds promise to advance progress in reducing the ongoing burden of COVID-19 across vulnerable populations.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2632657"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147304125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physician recommendation and vaccine hesitancy as key drivers of pneumococcal vaccination among older adults in China: a cross-sectional study using policy-stratified structural equation modeling. 医生推荐和疫苗犹豫是中国老年人肺炎球菌疫苗接种的关键驱动因素：一项使用政策分层结构方程模型的横断面研究

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-04-26 DOI: 10.1080/14760584.2026.2645379

Yuxing Wang, Shuai Yuan, Yuanruo Xie, Jianing Dai, Ling Zhu, Gang Liu, Zhujiazi Zhang, Lili You

{"title":"Physician recommendation and vaccine hesitancy as key drivers of pneumococcal vaccination among older adults in China: a cross-sectional study using policy-stratified structural equation modeling.","authors":"Yuxing Wang, Shuai Yuan, Yuanruo Xie, Jianing Dai, Ling Zhu, Gang Liu, Zhujiazi Zhang, Lili You","doi":"10.1080/14760584.2026.2645379","DOIUrl":"https://doi.org/10.1080/14760584.2026.2645379","url":null,"abstract":"Background: Pneumococcal disease causes severe illness in older adults. This study examined the impacts of physician recommendation, vaccine hesitancy, and regional policy differences on pneumococcal vaccination uptake in China.Research design and methods: A cross-sectional study was conducted among 13,363 adults aged ≥ 60 years in six Chinese cities using structural equation modeling, stratified by free and self-financed vaccination areas.Results: Mean age was 69.53 years, 54.74% female, with 22.79% vaccination rate. Vaccine hesitancy had a significant negative direct effect on vaccination uptake (β = -0.387, p < 0.001), while physician recommendation exerted the largest total positive effect (β = 0.349). In self-financed policy area, vaccine hesitancy was the strongest negative predictor (β = -0.529, p < 0.001), and diverse information sources mitigated hesitancy but showed a slight negative direct effect on uptake (β = -0.059).In the free-vaccine policy area, physician recommendation had a more pronounced direct effect (β = 0.305, p < 0.001), and better perceived health status was associated with suppressed uptake (β = -0.093).Conclusions: Vaccine attitudes often reflect generalized psychological constructs. Strategies must be tailored to policy contexts: enhancing information quality in self-financed areas and addressing complacency in free-vaccine settings. Multidimensional interventions should expand healthcare worker roles and optimize organizational logistics. Key limitations include the cross-sectional design and reliance on self-reported data.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2645379"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 in pediatrics in Latin America: six years later. 6年后，儿科的新冠肺炎

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-05-04 DOI: 10.1080/14760584.2026.2667741

María L Ávila-Aguero, Helena Brenes-Chacon, Luiza Helena Falleiros-Arlant, José Brea-Del Castillo, Alejandra Soriano-Fallas, Gabriela Naranjo-Zúñiga, Xavier Sáez-Llorens, Angela Gentile, Eduardo Lopez-Medina, Flor M Muñoz

{"title":"COVID-19 in pediatrics in Latin America: six years later.","authors":"María L Ávila-Aguero, Helena Brenes-Chacon, Luiza Helena Falleiros-Arlant, José Brea-Del Castillo, Alejandra Soriano-Fallas, Gabriela Naranjo-Zúñiga, Xavier Sáez-Llorens, Angela Gentile, Eduardo Lopez-Medina, Flor M Muñoz","doi":"10.1080/14760584.2026.2667741","DOIUrl":"10.1080/14760584.2026.2667741","url":null,"abstract":"Introduction: Six years later, the impact of the COVID-19 pandemic on children in Latin America remains profound. Even though they were considered less susceptible to the disease, infants have emerged as one of the most affected populations, with the pandemic exposing deep inequities and magnifying vulnerabilities. This paper is presented as a perspective from SLIPE on COVID-19, providing expert insight into the current epidemiological situation in the region.Areas covered: This review analyzes the effects of the COVID-19 pandemic on children's health and wellbeing, education, and immunization efforts. Vaccination coverage against COVID-19 in children is suboptimal, particularly among those with high-risk underlying conditions, and the disruption of routine immunization programs has led to outbreaks of vaccine preventable diseases in the region.Expert opinion: Addressing these challenges requires strengthening both COVID-19 vaccination strategies for high-risk pediatric populations and routine childhood immunization programs, along with effective communication to combat misinformation, prioritization of educational recovery, social protection, and resilient health systems. Recovery must focus on closing inequity gaps and placing children at the center of public policy to safeguard their future.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2667741"},"PeriodicalIF":4.8,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0